Background: Post-stroke dementia is defined as any dementia occurring after stroke, and includes vascular, degenerative and mixed dementia. The aim of this study was to assess the incidence of dementia and mild cognitive impairment (MCI) one year after stroke in a population free from pre-stroke cognitive decline, and to investigate the different aetiological subtypes of post-stroke dementia and MCI, using a novel method of subclassification in order to separate vascular causes of MCI or dementia from a neurodegenerative disease. Methods: All patients with a first-ever stroke and TIA admitted to the stroke unit of Asker and Bærum Hospital were invited. After 12 months, dementia and MCI were diagnosed. Sub-classification was made using MRI findings, the results of biomarkers in cerebrospinal fluid and the patients’ clinical cognitive profile. Results: 36 (19.6%) patients developed dementia during the first year after stroke and 69 (37.5%) developed MCI. Fourteen (13.3%) were diagnosed as suffering from degenerative cognitive disease, 34 (32.4%) from vascular cognitive disease, and 57 (54.3%) from mixed disease. Conclusion: Fifty-seven percent suffered from cognitive impairment one year after stroke and only one third from isolated vascular cognitive disease. Post-stroke cognitive impairment is complex with a high coexistence of vascular and degenerative changes.

Keywords:
Stroke, Cognitive impairment, Dementia
1.
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH: Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:280–292.
2.
Deschaintre Y, Richard F, Leys D, Pasquier F: Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 2009;73:674–680.
3.
Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR: Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997;277:813–817.
4.
Wagle J, Farner L, Flekkoy K, Wyller TB, Sandvik L, Eiklid KL, Fure B, Stensrod B, Engedal K: Association between ApoE ε4 and cognitive impairment after stroke. Dement Geriatr Cogn Disord 2009;27:525–533.
5.
Cechetto DF, Hachinski V, Whitehead SN: Vascular risk factors and Alzheimer’s disease. Expert Rev Neurother 2008;8:743–750.
6.
Hachinski V: The 2005 Thomas Willis Lecture: stroke and vascular cognitive impairment: a transdisciplinary, translational and transactional approach. Stroke 2007;38:1396.
7.
Leys D, Hénon H, Pasquier F: White matter changes and poststroke dementia. Dement Geriatr Cogn Disord 1998;9(suppl 1):25–29.
8.
Klimkowicz-Mrowiec A, Dziedzic T, Slowik A, Szczudlik A: Predictors of poststroke dementia: results of a hospital-based study in Poland. Dement Geriatr Cogn Disord 2006;21:328–334.
9.
Bejot Y, Aboa-Eboule C, Durier J, Rouaud O, Jacquin A, Ponavoy E, Richard D, Moreau T, Giroud M: Prevalence of early dementia after first-ever stroke: a 24-year population-based study. Stroke 2011;42:607–612.
10.
Leys D, Hénon H, Mackowiak-Cordoliani MA, Pasquier F: Poststroke dementia. Lancet Neurol 2005;4:752–759.
11.
Savva GM, Stephan BC: Epidemiological studies of the effect of stroke on incident dementia: a systematic review. Stroke 2010;41:e41–e46.
12.
Pendlebury ST, Rothwell PM: Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 2009;8:1006–1018.
13.
Patel MD, Coshall C, Rudd AG, Wolfe CD: Cognitive impairment after stroke: clinical determinants and its associations with long-term stroke outcomes. J Am Geriatr Soc 2002;50:700–706.
14.
Klimkowicz A, Dziedzic T, Slowik A, Szczudlik A: Incidence of pre- and poststroke dementia: Cracow stroke registry. Dement Geriatr Cogn Disord 2002;14:137–140.
15.
O’Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB, Rockwood K, Burns A, Gauthier S, DeKosky ST: Vascular cognitive impairment. Lancet Neurol 2003;2:89–98.
16.
Ganguli M, Snitz BE, Saxton JA, Chang CC, Lee CW, Vander BJ, Hughes TF, Loewenstein DA, Unverzagt FW, Petersen RC: Outcomes of mild cognitive impairment by definition: a population study. Arch Neurol 2011;68:761–767.
17.
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–308.
18.
Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de LM, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van DC, Visser P, Petersen RC: Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240–246.
19.
Jorm AF, Jacomb PA: The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med 1989;19:1015–1022.
20.
Jorm AF: The Informant Questionnaire on cognitive decline in the elderly (IQCODE): a review. Int Psychogeriatr 2004;16:275–293.
21.
Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
22.
Eddy JR, Sriram S: Clock-drawing and telling time as diagnostic aids. Neurology 1977;27:595.
23.
Reitan RM: Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills 1958;8:271–276.
24.
Randolph C, Tierney MC, Mohr E, Chase TN: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998;20:310–319.
25.
Goldstein LB, Bertels C, Davis JN: Interrater reliability of the NIH stroke scale. Arch Neurol 1989;46:660–662.
26.
Sulter G, Steen C, De KJ: Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke 1999;30:1538–1541.
27.
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE, III: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35–41.
28.
Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521–1526.
29.
Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J: Atrophy of medial temporal lobes on MRI in ‘probable’ Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55:967–972.
30.
Stenset V, Bjornerud A, Fjell AM, Walhovd KB, Hofoss D, Due-Tonnessen P, Gjerstad L, Fladby T: Cingulum fiber diffusivity and CSF T-τ in patients with subjective and mild cognitive impairment. Neurobiol Aging 2011;32:581–589.
31.
de Groot JC, de Leeuw FE, Oudkerk M, van GJ, Hofman A, Jolles J, Breteler MM: Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol 2000;47:145–151.
32.
World Health Organization: The ICD-10 Classification of Mental and Behavioural Disorders: diagnostic criteria for research. Geneva, World Health Organization, 1993.
33.
Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984;141:1356–1364.
34.
Thommessen B, Thoresen GE, Bautz-Holter E, Laake K: Screening by nurses for aphasia in stroke – the Ullevaal Aphasia Screening (UAS) test. Disabil Rehabil 1999;21:110–115.
35.
Desmond DW, Erkinjuntti T, Sano M, Cummings JL, Bowler JV, Pasquier F, Moroney JT, Ferris SH, Stern Y, Sachdev PS, Hachinski VC: The cognitive syndrome of vascular dementia: implications for clinical trials. Alzheimer Dis Assoc Disord 1999;13(suppl 3): S21–S29.
36.
Moorhouse P, Rockwood K: Vascular cognitive impairment: current concepts and clinical developments. Lancet Neurol 2008;7:246–255.
37.
Hénon H, Durieu I, Guerouaou D, Lebert F, Pasquier F, Leys D: Poststroke dementia: incidence and relationship to prestroke cognitive decline. Neurology 2001;57:1216–1222.
38.
Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD: Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer’s disease. Lancet 1999;354:919–920.
39.
Wagle J, Farner L, Flekkoy K, Wyller TB, Sandvik L, Eiklid KL, Fure B, Stensrod B, Engedal K: Cognitive impairment and the role of the ApoE ε4-allele after stroke – a 13 months follow-up study. Int J Geriatr Psychiatry 2010;25:833–842.
40.
Ballard CG, Morris CM, Rao H, O’Brien JT, Barber R, Stephens S, Rowan E, Gibson A, Kalaria RN, Kenny RA: APOE ε4 and cognitive decline in older stroke patients with early cognitive impairment. Neurology 2004;63:1399–1402.
41.
Kester MI, Scheltens P: Dementia: the bare essentials. Pract Neurol 2009;9:241–251.
42.
Viswanathan A, Rocca WA, Tzourio C: Vascular risk factors and dementia: how to move forward? Neurology 2009;72:368–374.
43.
Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A: Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population-based study. BMJ 2001;322:1447–1451.
44.
Hénon H, Pasquier F, Leys D: Poststroke dementia. Cerebrovasc Dis 2006;22:61–70.
45.
Hénon H, Pasquier F, Durieu I, Godefroy O, Lucas C, Lebert F, Leys D: Preexisting dementia in stroke patients. Baseline frequency, associated factors, and outcome. Stroke 1997;28:2429–2436.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.